Login / Signup

An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade.

Cesare Di NittoDomenico RavazzaEttore GilardoniThomas LookMiaomiao SunEleonora ProdiVlad MoisoiuChristian PellegrinoMarkus G ManzEmanuele PucaMichael WellerTobias WeissDario NeriRoberto De Luca
Published in: Journal for immunotherapy of cancer (2024)
Our results provide the rationale to explore the combination of F8(scDb)-IL7 with anti-PD-1 antibodies for the treatment of patients with cancer.
Keyphrases
  • clinical trial
  • cancer therapy
  • type iii